FLORENCE, Ky. -- PediaMed Strengthens Outreach to Pediatricians to Fight the Most Common Eye Disease among Children - "Pink Eye"
PediaMed - The Pediatrics Company(TM) announced today that it has entered into a co-promotion agreement with Allergan, Inc. (NYSE:AGN) in the United States pediatric market for Allergan's ZYMAR(R) ophthalmic solution, a treatment for bacterial conjunctivitis, the common eye infection known to many as "pink eye."
Bacterial conjunctivitis is an inflammation caused by bacterial infection of the conjunctiva, the thin membrane that lines the outside of the eyeball and the inside of the eyelids. Most often, the infection can be characterized by swelling, redness, and itching eyes, as well as the presence of yellow, green or watery discharge from the eyes that may collect overnight and become crusty.
"Bacterial forms of conjunctivitis are extremely contagious, can spread among children very quickly and this is therefore a great concern for schools and day care centers" said Cameron Durrant, M.D., M.B.A., President, PediaMed - The Pediatrics Company. "A diagnosis of bacterial conjunctivitis often worries parents since it can impact school or day care attendance. We are delighted to join forces with Allergan, a recognized leader in eye care, to combat this concern, and alert pediatricians and parents that usually 24 hours after beginning treatment with an antibiotic, children are able to return to their regular routine."
"We are excited that PediaMed will be promoting ZYMAR(R) in the United States pediatric market," said Julian Gangolli, Allergan's Corporate Vice President and President of U.S. Pharmaceuticals. "ZYMAR(R) is currently the leading treatment for bacterial conjunctivitis in the United States ophthalmology market, and we are confident in PediaMed's ability to replicate the product's success with pediatric health care providers." This is the second transaction that Allergan and PediaMed have entered into within the last year. In August 2004, Allergan and PediaMed entered into an agreement to co-promote Allergan's TAZORAC(R) product to the United States pediatric market.
The National Guideline Clearinghouse (NGC), an initiative of the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services, supported the American Optometric Association guidelines put out in the 2002 "Care of the patient with conjunctivitis, 2nd Edition" report. It states that the ideal method of treating bacterial conjunctivitis is to treat with antibiotics that can lessen the patient's symptoms, the duration and chances of recurrence of the disease(1). ZYMAR(R) belongs to a new class of anti-infectives for ophthalmic use that has been shown to fight some bacteria that may not be effectively treated by other medications.
A specialty pharmaceutical company focusing exclusively on the pediatric space, PediaMed will be responsible for ZYMAR(R) commercialization to the United States pediatric market, with Allergan continuing to promote to ophthalmologists, optometrists and other eye care professionals.
About PediaMed - The Pediatrics Company(TM)
A company devoted exclusively to the health of children. PediaMed identifies, develops and markets branded prescription pharmaceuticals that improve the health and well-being of infants, children, adolescents and young adults. Founded in 1999 and headquartered in Greater Cincinnati, PediaMed is a member of the Union Springs portfolio of companies. For more information, visit the PediaMed website at www.pediamedpharma.com.
About Allergan, Inc.
Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives. For more information, visit the Allergan website at www.allergan.com.
Forward Looking Statements
The information presented in this release contains forward-looking statements, including, among other statements, the statements by Dr. Durrant and Mr. Gangolli, that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The reader is cautioned not to rely on such forward-looking statements.
COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group